Association between implanted cardioverter-defibrillators and mortality for patients with left ventricular ejection fraction between 30% and 35.
Jason H WasfyAditya AchantaMichael K HidrueSarah UrbutAndrea L AxtellAdam N BermanYunong ZhaoJulian ChenSarah GustusMichael H PicardPublished in: Open heart (2023)
ICD therapy was not associated with reduced mortality near the conventional LVEF threshold of 35%. Although this treatment design cannot definitively demonstrate lack of efficacy, our results are concordant with available prior trial data. A definitive, well-powered trial is needed to answer the important clinical question of primary prevention ICD efficacy between LVEF 30% and 35%.
Keyphrases
- ejection fraction
- aortic stenosis
- left ventricular
- study protocol
- phase iii
- cardiovascular events
- phase ii
- clinical trial
- cardiac resynchronization therapy
- risk factors
- heart failure
- big data
- randomized controlled trial
- squamous cell carcinoma
- aortic valve
- hypertrophic cardiomyopathy
- cardiovascular disease
- mitral valve
- combination therapy
- artificial intelligence